IMVT stock news · Immunovant, Inc.

Stories about Immunovant, Inc. (IMVT) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for IMVT

Follow Immunovant, Inc. (IMVT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Free on the App Store and Google Play, or on the web.

Nov 9, 2026, 7:16 AM ET · Market
Immunovant shared its financial results and business updates for the second quarter.
Neutral
Immunovant filed an 8-K announcing its fiscal second-quarter and six-month results. The filing text gives no figures or business updates, so it does not change the company outlook.
Oct 14, 2026, 5:05 AM ET · Results
Immunovant shares the full details from its earnings call for the first quarter of 2027.
Good for IMVT
Immunovant expects to launch brepocitinib by September's end and has begun another phase 3 study. FDA action and several study results remain pending, but current progress supports a brighter business picture.